Merger looks to create bacteriophages to counter antibiotic resistance 14-May-2019 By Maggie Lynch AmpliPhi Biosciences and C3J Therapeutics merge to focus on the development of phage-based therapeutic candidates for antibiotic resistance.
Biopharm boosts sales for Nabi Biopharm boosts sales for Nabi 20-Feb-2003 Nabi Biopharmaceuticals saw biopharmaceutical product sales - driven by strong growth in sales of Nabi-HB - reaching record levels of $89.5 million (€83m) in 2002, a 22 per cent increase from 2001 levels.